Bessemer Group Inc. Has $485,000 Stake in Humana Inc. $HUM

Bessemer Group Inc. lifted its position in shares of Humana Inc. (NYSE:HUM) by 11.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,983 shares of the insurance provider’s stock after purchasing an additional 199 shares during the quarter. Bessemer Group Inc.’s holdings in Humana were worth $485,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Cary Street Partners Investment Advisory LLC raised its position in Humana by 63.9% in the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock valued at $31,000 after buying an additional 46 shares during the last quarter. Zions Bancorporation National Association UT purchased a new stake in Humana in the 1st quarter valued at $37,000. CVA Family Office LLC raised its position in Humana by 63.4% in the 2nd quarter. CVA Family Office LLC now owns 219 shares of the insurance provider’s stock valued at $54,000 after buying an additional 85 shares during the last quarter. Ransom Advisory Ltd purchased a new stake in Humana in the 1st quarter valued at $66,000. Finally, Transamerica Financial Advisors LLC raised its position in Humana by 1,027.6% in the 1st quarter. Transamerica Financial Advisors LLC now owns 327 shares of the insurance provider’s stock valued at $87,000 after buying an additional 298 shares during the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Stock Down 2.7%

Shares of NYSE:HUM opened at $278.02 on Monday. The company has a market capitalization of $33.44 billion, a PE ratio of 21.34, a price-to-earnings-growth ratio of 1.71 and a beta of 0.42. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95. The business has a fifty day moving average price of $281.34 and a two-hundred day moving average price of $258.62. Humana Inc. has a 1 year low of $206.87 and a 1 year high of $315.35.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be paid a dividend of $0.885 per share. The ex-dividend date is Friday, December 26th. This represents a $3.54 annualized dividend and a dividend yield of 1.3%. Humana’s dividend payout ratio is presently 27.17%.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on HUM shares. Royal Bank Of Canada increased their price target on Humana from $283.00 to $322.00 and gave the company an “outperform” rating in a research report on Thursday, August 21st. Wall Street Zen lowered Humana from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Sanford C. Bernstein increased their price target on Humana from $269.00 to $341.00 and gave the company an “outperform” rating in a research report on Friday, September 5th. Robert W. Baird lowered their price target on Humana from $300.00 to $297.00 and set a “neutral” rating for the company in a research report on Friday, July 25th. Finally, The Goldman Sachs Group began coverage on Humana in a research report on Tuesday, October 14th. They issued a “sell” rating and a $235.00 price target for the company. Eight investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $297.58.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.